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Circulating levels of Trimethylamine N-oxide (TMAO), a gut microbiome-mediated metabolite 
related to Western diet1, 2, have been shown to be associated with risk stratification and outcome in 
patients with heart failure (HF) with reduced ejection fraction (HFrEF)3-6. The aim of the present study 
was to assess the associations between TMAO with outcomes in patients with HF with preserved 
ejection fraction (HFpEF).  
To investigate the recently identified link between the gut and HF (namely: “gut hypothesis”), 
TMAO levels were measured in 118 patients with HFpEF, 38 patients with HFrEF, and 40 healthy 
volunteer participants (sex/age matched) with available baseline plasma samples from the Developing 
Imaging And plasMa biOmarkers iN Describing Heart Failure With Preserved Ejection Fraction 
(DIAMONDHFpEF) cohort, a prospective, observational, single-centre study aimed at developing 
imaging and plasma biomarkers of novel pathophysiological patterns in HFpEF [NCT03050593]7. 
Plasma levels of TMAO were measured using liquid chromatography-tandem mass spectrometry, a 
high throughput, reproducible, and accurate method3, 5, 8. BNP was measured using a commercial 
immunoassay (Siemens, Erlangen, Germany). All patients had blood tests, transthoracic 
echocardiography (TTE, Philips iE33, Amsterdam, Netherlands), and cardiac magnetic resonance 
(CMR) imaging (Siemens Skyra Erlangen, Germany) during the same visit. Primary outcomes were 
defined as the composite endpoint of all-cause mortality or hospitalisation for HF at 18 months (short-
term) and at 60 months (long-term).  
Baseline patient demographics, blood chemistry, echocardiographic, and CMR measurements 
are shown in Table 1. Patients with HFpEF had higher body mass index (BMI), higher prevalence of 
systemic hypertension and atrial fibrillation, and less coronary artery disease. HFpEF patients had lower 
BNP levels as compared to HFrEF patients [140 (55-252) pg/mL vs. 345 (167-605) pg/mL, p<0.001]. 
HFrEF patients showed higher end-diastolic [140.8 (107.8-164.9) ml/m2 vs 77.2 (65.9-91.9) ml/m2] and 
end-systolic [97.8 (68.7-128.5) ml/m2 vs 33.1 (27.4-41.9) ml/m2] volumes on CMR (p<0.01), and higher 
LV filling pressures (E/e’ ratio) [13.1 (11.5-19.9) vs. 11.5 (9.1-16.6), p=0.023] on TTE (Table 1). HF 
patients showed elevated circulating TMAO levels when compared to sex/age matched healthy controls 
[HFpEF 6.6 (4.3-12.2) µmol/L, adj. p=0.003; HFrEF 8.4 (3.7-13.8) µmol/L, adj. p=0.006; vs. control 
4.0 (3.2-5.3) µmol/L], but no differences were observed between HF phenotypes. TMAO was positively 
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correlated with age, BMI, E/e’, and BNP levels, and negatively correlated with eGFR (Table 1). A total 
of 27 events (13 deaths and 14 HF hospitalisation) were recorded in the HFpEF cohort over a follow-
up of 18 months (short-term), and 55 events (32 deaths and 23 hospitalisation) over a follow up of 60 
months (long-term). For short-term outcomes, Cox proportional hazards regression showed that HFpEF 
patients with a circulating TMAO level exceeding a cut-off of 5 µmol/L (derived from the upper quartile 
of the control population in this study as a whole integer) showed a 4-fold increase in risk of an event 
[HR (95% CI) 3.82 (1.15-12.69), p=0.029]. TMAO remained significantly associated with outcome 
when adjusted for age, sex, BMI, and eGFR [3.66 (1.03-13.04) p=0.045]. However, TMAO was not 
significantly associated with events as a continuous, univariate marker (p=0.109). For long-term 
outcomes, at the cut-off point of 5 µmol/L, TMAO was significantly associated with outcomes [2.74 
(1.34-5.61) p=0.006], and showed associations when adjusted for confounders [2.45 (1.12-5.35) 
p=0.025]. As a continuous variable, TMAO was associated with outcome as a univariate marker [1.98 
(1.11-3.55) p=0.021], but did not retain this when adjusted for confounders. When mortality was 
investigated, as a continuous variable, TMAO was significantly associated with outcome both as a 
univariate marker [2.40 (1.11-5.18) p=0.025], and after adjustment [3.53 (1.34-9.33) p=0.11]. As 
elevation of BNP levels is less pronounced in HFpEF patients, Kaplan-Meier survival analyses were 
performed to compare the use of TMAO as a predictor of outcome in HFpEF patients with low BNP 
levels (cut-off value of 140 pg/mL and 250 pg/mL, derived from the ESC guidelines 9) and compared 
to those with more pronounced elevations of circulating BNP (≥140 pg/mL and ≥250 pg/mL) (Figure 
1). When all HFpEF patients were stratified by TMAO and BNP levels, those with lower levels of both 
biomarkers reported the greatest survival, with a gradual increase of risk when one or both biomarkers 
were elevated for short- (log-rank test, p≤0.004, Figure 1A and 1C) and long-term outcomes (log-rank 
test, p≤0.010, Figure 1B and 1D). When compared to patients with lower levels of both biomarkers, 
BNP alone, when stratified at 140 pg/mL, showed significant changes in survival for short-term 
(p=0.04), but not long-term (p=0.11) outcomes, whereas TMAO alone, when stratified at 5 µmol/L, 
showed significant changes in survival for both short- and long-term outcomes (p≤0.04, Figure 1A and 
1B). When stratified at 250 pg/mL, both BNP alone and TMAO alone showed significant changes in 
survival for both outcomes (p≤0.03, Figure 1C and 1D).   
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The present study indicates that TMAO levels were elevated to a similar extent in HFpEF and 
HFrEF patients in comparison to cardiovascular disease-free participants, in line with a previous 
report10. Furthermore, our findings suggest the possible use of TMAO for risk stratification of long-
term mortality. In addition, our results support the hypothesis that TMAO levels could aid in stratifying 
HFpEF patients who would otherwise be classified as low-risk based on BNP levels. Indeed, when a 
cut-off level was used for TMAO, associations with adverse outcomes in HFpEF patients in which 
BNP, the ‘gold standard’ biomarker in HFrEF, was less elevated were observed. TMAO levels also 
increased with higher LV filling pressure and BNP levels, suggesting association with worsening of HF 
with progressive diastolic dysfunction, in line with a previous report showing association between 
TMAO levels, HF severity, and diastolic dysfunction11. To date, only one study has investigated the 
prognostic value of TMAO in HFpEF10, with inconclusive results. The present report suggests a role 
for TMAO in the clinical management of HFpEF patients, allowing for better risk stratification, 
unachievable with BNP alone12, 13. Further, therapeutic intervention of the gut microbiome may offer 
potential additive treatments for HF. Our data supports the notion of combined multimarker strategies, 
in particular if circulating and imaging biomarkers from different pathophysiological patterns are 
combined14. As study limitations, patients were recruited from a single centre with a relatively small 
sample size that does not allow extensive prediction modelling to be performed. In addition, data 
regarding dietary intake and antibiotic treatment that could influence TMAO levels were not available.    
 In conclusion, as natriuretic peptides are not as highly elevated in HFpEF compared to HFrEF, 
elevated circulating levels of TMAO may provide utility in risk stratification of HFpEF where this and 
other biomarkers show equivocal levels. Therefore, the combined use of BNP and TMAO may be useful 
in patients with HFpEF. 
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Table 1. Patient demographics. 
 HF (n=156) HFpEF (n=118) HFrEF (n=38) Control (n=40) 
HFpEF 
vs. 
HFrEF 
Correlation with 
TMAO full population 
(rs) 
p value 
Demographics        
Age (years) 73 (67-78) 73 (65-78) 72 (62-77) 72 (69-77) ns 0.154 0.031 
Male (%) 49 49 50 53% ns - - 
Body Mass Index (kg/m2) 32.2 (26.4-38.5) 33.8 (28.4-39.7) 27.5 (24.7-32.3) - < 0.001 0.158 0.027 
NYHA (I/II/III/IV) 53/59/40/4 37/46/31/4 16/13/9/0 - ns - - 
Hypertension (%) 81 91 54 - <0.001 - - 
Coronary Artery Disease (%) 29 21 50 - <0.001 - - 
Diabetes Mellitus (%) 46 49 39 - ns - - 
Atrial Fibrillation (%) 38 79 24 - 0.017 - - 
eGFR (mL/min/1.73m2) 68 (48-85) 69 (50-85) 65 (48-78) - ns -0.527 <0.001 
CMR        
LVEDVi (ml/m2) 85.9 (69.6-106.8) 77.2 (65.9-91.9) 140.8 (107.8-164.9) 80.4 (72.34-89.6) <0.001 0.028 0.736 
LVESVi (ml/m2) 39.2 (29.7-57.6) 33.1 (27.4-419) 97.8 (68.7-128.5) 32.6 (29.2-37.8) <0.001 0.005 0.953 
LVEF (%) 52.8 (41.8-58.6) 55.4 (51.8-60.1) 28.3 (20.7-36.4) 57.3 (55.4-59.77) <0.001 -0.001 0.991 
Echocardiography    
 
   
E/e’ 12.3 (9.7-19.9) 11.5 (9.1-16.6) 13.1 (11.5-19.9) - 0.023 0.287 <0.001 
Biomarkers        
BNP (pg/mL) 170 (80-336) 140 (55-252) 345 (167-605) - <0.001 0.221 0.006 
TMAO (µmol/L) 7.0 (4.2-12.5) 6.6 (4.3-12.2) 8.4 (3.7-13.8) 4.0 (3.2-5.3) ns - - 
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HF = heart failure; HFpEF = heart failure with preserved ejection fraction; HFrEF = heart failure with reduced ejection fraction; TMAO = trimethylamine N-oxide; BNP = B-
type natriuretic peptide; NYHA = New York Heart Association functional class; eGFR = estimated glomerular filtration rate; LVEDVi: Left ventricular end diastolic volume 
indexed; LVESVi: Left ventricular end systolic volume indexed; LVEF = left ventricular ejection fraction; E/e’= Peak modal transmitral flow velocity in early diastole / 
Pulse wave tissue Doppler imaging peak modal velocity in early diastole; rs = Spearman’s rho. Data expressed as median (IQR) for continuous variables and % of total for 
categorical variables.  
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Figure 1.  
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Figure 1. Kaplan-Meier analysis of survival at 18 months (short term), (A) and (C), and 60 months (long-term), (B) and (D),  for all-cause mortality 
or heart failure hospitalisation in patients with preserved ejection fraction (HFpEF) with neither biomarker elevated, only trimethylamine N-oxide 
(TMAO) elevated (5 µmol/L), only B-type natriuretic peptide (BNP) elevated (>140 pg/mL in (A) and (B) or >250 pg/mL in (C) and (D)) or both 
biomarkers elevated. 
 
 
